AWM
TXMD icon

Apollon Wealth Management’s TherapeuticsMD TXMD Stock Holding History

Apollon Wealth Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-300
Closed -$6K – 807
2022
Q1 		$6K Sell
300
-29
-9% -$456 ﹤0.01% 757
2021
Q4 		$6K Buy
+329
New +$9.86K ﹤0.01% 759

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Apollon Wealth Management's TXMD Position: Q2 2022 in Review

Apollon Wealth Management sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 300 shares — an estimated $6K sold.

Apollon Wealth Management first reported a position in TXMD in Q4 2021 and held it in 2 quarters. The position peaked at $6K in Q1 2022. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Apollon Wealth Management reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Apollon Wealth Management sold 300 TherapeuticsMD shares in Q2 2022, an estimated $6K.
  • Apollon Wealth Management first reported a position in TherapeuticsMD in Q4 2021 and held it in 2 quarters.
  • Apollon Wealth Management's TherapeuticsMD position peaked at $6K in Q1 2022.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Apollon Wealth Management's 13F filing for Q2 2022, filed 11 Aug 2022.